Accurate Education - Module 4: POST-Operative Nutraceutical Management

Peri-operative Pain Management:

Module 4:

POST-Operative Nutraceutical Management

This section covers Module 3 of the Peri-operative Pain Protocol — POST-Operative Dietary & Nutritional Management — as part of a comprehensive approach to the management of pain associated with upcoming, planned surgical procedures. These procedures include those for the management of chronic joint, neck and back pain such as spinal fusions, artificial disc replacements, total joint replacements as well as less invasive procedures.

Perioperative – Before, During and After Surgery
Preoperative – Before Surgery
Postoperative – After Surgery

This guide is not intended to replace appropriate nutritional guidance that should be provided by a dietitian regarding perioperative dietary management. Please consult with your surgeon for dietary guidance including referral to a dietitian.

See:

Peri-Operative Pain Management (P-OPM)

Key to Links:

Grey text – handout
Red text – another page on this website
Blue text – Journal publication

Definitions and Terms Related to Pain

Module 4:

POST-Operative Nutraceutical Management

Introduction – The Peri-operative Pain Management Protocol

The goal of the peri-operative pain protocol is to manage pain starting with the pre-operative period (4–6 weeks before surgery) through the post-operative period (up to 12 weeks after surgery. This protocol includes dietary & nutritional management as well as the use of nutraceuticals during both the pre-operative and post-operative periods. It is designed to reduce not only post-operative pain, but importantly, to also reduce the transitioning of post-operative pain from becoming chronic pain.

This peri-operative pain management protocol applies the principles of the 4-D chronic pain management protocols described here.The 4-D protocols engage lifestyle management as well as the use of prescription medications and therapeutic nutraceuticals based on the anti-inflammatory diet.

Strategic Framework for Protocol Development – A Modular Approach

Protocol Structure and Development Sequence

The peri-operative protocol is divided into the pre-operative period (4–6 weeks before surgery) and the post-operative period ((0–12 weeks after surgery). The pre-operative and post-operative protocols are each divided into two modules (1) Dietary & Nutritional Management and (2) Nutraceutical Management.

The four modules are presented in this order, as each builds on the prior:

Pre-operative Management (4–6 weeks before surgery)

Module 1: Dietary and Nutritional Management
Module 2: Nutraceutical Management

Post-operative Management (0–12 weeks after surgery)

Module 3: Dietary and Nutritional Management
Module 4: Nutraceutical Management

Outlined in the protocol are breakdowns of the responsibilities for both the surgical team and the pain management team regarding the assessment and management of the patient’s pain. Topics include pre-operative and post-operative dietary & nutritional management and recommended nutraceutical management.

Peri-operative Considerations for Patients on Chronic Opioid Management

Of note, this protocol has been established to facilitate appropriate and effective peri-operative pain management specifically directed at those pain patients who have been taking opioids chronically for their pain. Both the presence of chronic pain, as well as the long-term use of opioids, introduces significant variables that impact appropriate choices for managing the patient’s pain. An additional section is forthcoming for the management of peri-operative pain management directed at those patients with acute pain and/or non-opioid dependent pain.

—

OVERVIEW AND RATIONALE

This module provides a structured protocol for restarting and managing the 4-D Protocol’s nutraceuticals during the 12-week postoperative period. The protocol serves three simultaneous objectives:

1. Safely restart held nutraceuticals in a phased sequence once hemostasis is assured and surgical clearance is obtained.

2. Target the acute-to-chronic pain transition window (weeks 2–12) with domain-specific nutraceutical interventions designed to modulate the neuroinflammatory, oxidative stress, and mitochondrial dysfunction pathways that drive pain chronification.

3. Restore the patient’s full 4-D Protocol nutraceutical regimen by 12 weeks postoperatively, with adjustments based on postoperative biomarker reassessment.

The central clinical challenge of this module is that the nutraceuticals held preoperatively for surgical safety (curcumin, resveratrol, quercetin, boswellia, CoQ10, ALA, and others) are precisely the agents most needed to combat the postoperative inflammatory surge and prevent pain chronification. The protocol therefore prioritizes rapid, safe reintroduction.

—

SECTION 1:

NUTRACEUTICAL RESTART PRINCIPLES

1A. General Restart Criteria

Before restarting any held nutraceutical, the following conditions should be met:

Hemostasis is clinically assured (no active bleeding, stable drain output if applicable, no expanding hematoma)
Surgeon clearance has been obtained (either explicitly or per pre-established protocol communicated preoperatively)
The patient is tolerating oral intake
No active surgical complications (wound dehiscence, infection, hematoma) that would alter the risk-benefit calculation

1B. Restart Timing Framework

The restart protocol uses a three-tier system based on the reason the nutraceutical was held:

Tier 1 (Restart Post-Op Day 1–2): Nutraceuticals held for brief pharmacologic reasons (NAC — 24-hour hold) and nutraceuticals that were continued through surgery but may need dose adjustment
Tier 2 (Restart Week 1–2): Nutraceuticals held for bleeding risk, once hemostasis is clinically assured and the patient is past the acute surgical bleeding window
Tier 3 (Restart Week 2–4): Nutraceuticals held for cardiovascular or metabolic concerns, or those for which a more conservative restart is preferred

—

SECTION 2:

PHASED RESTART SCHEDULE

Phase A:

Immediate Postoperative (POD 0–2) — Continued Agents + NAC Restart

The following nutraceuticals were continued through surgery (Category A from Module 2) and should be resumed at their preoperative doses as soon as the patient is tolerating oral intake:

1. Omega-3 (EPA/DHA) — Resume at 2–4 g/day. The most important nutraceutical to maintain continuously. Preoperative omega-3 supplementation has demonstrated reduced postoperative pain (VAS 10.9 vs. 25 mm) and CRP levels at 24 hours.[1]

2. Melatonin — Resume at preoperative dose (3–10 mg nightly). Supports sleep during the critical early recovery period; may reduce postoperative delirium risk in elderly patients.[1]

3. Vitamin D3 — Resume at maintenance dose (2,000 IU/day). Surgery causes acute vitamin D depletion.[2]

4. B-Complex (including B12) — Resume at preoperative dose. Thiamine requirements increase during the surgical inflammatory response. B12 supplementation has been shown to improve short-term functional and mental health outcomes and decrease neuropathic analgesic consumption postoperatively.[3][4]

5. P5P — Resume at preoperative dose. Supports neurotransmitter synthesis during the period of maximal descending modulatory pathway stress.

6. Magnesium — Resume oral magnesium glycinate at preoperative dose (400–800 mg elemental Mg/day). Complements any IV magnesium administered perioperatively by the surgical team. Oral and IV magnesium serve different temporal roles — IV provides acute perioperative NMDA antagonism, while oral maintains sustained tissue levels.[4][5][6]

7. PEA (if continued through surgery) — Resume at preoperative dose. PEA’s PPAR-α agonism, mast cell modulation, and glial cell regulation are particularly relevant during the acute postoperative inflammatory phase.[5][7][8]

NAC Restart (POD 1):

8. NAC — Restart on POD 1 at preoperative dose (600–1,200 mg/day) once hemodynamically stable. NAC was held only 24 hours preoperatively. Its role as a glutathione precursor makes early restart valuable for managing the postoperative oxidative stress surge. Oral NAC at standard doses does not carry the anaphylactoid risk associated with IV NAC.[1][9]

Phase B:

Early Postoperative (Days 7–14) — Bleeding-Risk Agents Restart

Once hemostasis is clinically assured (typically by postoperative day 7–10 for most orthopedic procedures), the following nutraceuticals held for bleeding risk can be restarted. For spine fusion patients, a more conservative timeline (day 10–14) is recommended given the higher consequences of postoperative bleeding:

9. Curcumin — Restart at full therapeutic dose. Curcumin is a priority restart agent. Preclinical evidence demonstrates that postoperative curcumin significantly reverses mechanical hyperalgesia and facilitates recovery from surgery, with dose-dependent effects. Notably, repeated curcumin treatment after surgery was effective even though preoperative curcumin showed no preventive value — supporting the rationale for postoperative rather than preoperative emphasis. An RCT in laparoscopic cholecystectomy patients showed curcumin reduced pain scores by 50% at weeks 1–2 and reduced analgesic tablet usage from 39 to 7 tablets over 3 weeks. Curcumin co-administered with opioids (hydromorphone) showed synergistic pain reduction via suppression of the SDF-1/CXCR4 pathway and NF-κB-mediated proinflammatory cytokine production in the dorsal root ganglia — directly relevant to this opioid-treated population. Additionally, curcumin induces peripheral antinociception through both opioidergic and cannabinoidergic mechanisms, activating μ, δ, and κ opioid receptors and CB1/CB2 cannabinoid receptors, and potentiating endocannabinoid signaling.[4][5][10][11]

10. Resveratrol — Restart at preoperative dose. Supports the oxidative stress domain and provides anti-inflammatory coverage complementary to curcumin.[1]

11. Quercetin — Restart at preoperative dose. Anti-inflammatory and antioxidant properties support the transition from acute inflammation to resolution.[1]

12. Boswellia — Restart at preoperative dose. 5-lipoxygenase inhibition provides anti-inflammatory coverage through a pathway distinct from curcumin’s COX/NF-κB mechanism.[4]

13. Sulforaphane — Restart at preoperative dose. Nrf2 pathway activation supports the antioxidant defense system during the period of maximal oxidative stress.

14. Taurine — Restart at preoperative dose. Antioxidant and neuromodulatory support.

15. Agmatine — Restart at preoperative dose. NMDA receptor antagonist properties are particularly relevant during the early postoperative period when central sensitization risk is highest. Agmatine’s imidazoline receptor agonism also provides additional analgesic mechanisms.

16. PEA (if held preoperatively) — Restart at preoperative dose if a conservative hold approach was used in Module 2.

—

Phase C: Subacute Postoperative (Weeks 2–4) — Metabolic/Cardiovascular Agents Restart

17. CoQ10 — Restart at preoperative dose once the patient is hemodynamically stable and past the acute surgical period. CoQ10 was held for potential hypotensive effects. Its restart is a priority for the mitochondrial dysfunction domain, as surgical stress depletes mitochondrial energy reserves.[1]

18. Alpha-Lipoic Acid (ALA) — Restart at preoperative dose once postoperative glucose management is stable. ALA was held for glucose metabolism concerns. Monitor blood glucose during the restart period, particularly in diabetic patients.[1]

19. Acetyl-L-Carnitine (ALC) — Restart at preoperative dose. Supports mitochondrial fatty acid transport and has demonstrated neuroprotective and analgesic properties relevant to the subacute recovery phase.

20. Nicotinamide Riboside (NR) — Restart at preoperative dose. NAD+ repletion supports mitochondrial bioenergetics during the energy-demanding recovery and rehabilitation phase.[12]

21. D-Ribose — Restart at preoperative dose once glucose management is stable. ATP synthesis support for mitochondrial energy production during rehabilitation.

—

SECTION 3:

Master POST-Operative Nutraceutical Restart Schedule

Nutraceutical	4D Domain(s)	POD 0–2	Days 7–14	Weeks 2–4	Weeks 4–12	Restart Priority	References
Omega-3 (EPA/DHA)	Inflammation	✓ Continue	✓	✓	✓	Continuous	[1]
Melatonin	Neuroinflammation	✓ Continue	✓	✓	✓	Continuous	[1]
Vitamin D3	Inflammation/Bone	✓ Continue	✓	✓	✓	Continuous	[2]
B-Complex (incl. B12)	Neuroinflammation	✓ Continue	✓	✓	✓	Continuous	[3][4]
P5P	Neuroinflammation	✓ Continue	✓	✓	✓	Continuous	—
Magnesium	All 4 domains	✓ Continue	✓	✓	✓	Continuous	[4][5][6]
PEA	Neuroinflammation	✓ Continue*	✓	✓	✓	Continuous or Phase B	[5][7][8]
NAC	Oxidative Stress	✓ Restart POD 1	✓	✓	✓	Tier 1	[1][9]
Curcumin	Inflammation	✗	✓ Restart	✓	✓	Tier 2 — HIGH	[4][5][10][11]
Resveratrol	Oxidative Stress	✗	✓ Restart	✓	✓	Tier 2	[1]
Quercetin	Inflammation/OS	✗	✓ Restart	✓	✓	Tier 2	[1]
Boswellia	Inflammation	✗	✓ Restart	✓	✓	Tier 2	[4]
Sulforaphane	Oxidative Stress	✗	✓ Restart	✓	✓	Tier 2	—
Taurine	OS/Neuro	✗	✓ Restart	✓	✓	Tier 2	—
Agmatine	Neuroinflammation	✗	✓ Restart	✓	✓	Tier 2 — HIGH	—
CoQ10	Mitochondrial	✗	✗	✓ Restart	✓	Tier 3	[1]
Alpha-Lipoic Acid	OS/Mitochondrial	✗	✗	✓ Restart	✓	Tier 3	[1]
Acetyl-L-Carnitine	Mitochondrial	✗	✗	✓ Restart	✓	Tier 3	—
Nicotinamide Riboside	Mitochondrial	✗	✗	✓ Restart	✓	Tier 3	[12]
D-Ribose	Mitochondrial	✗	✗	✓ Restart	✓	Tier 3	—

PEA: Continuous if continued through surgery per Module 2; restart in Phase B if held.

OS = Oxidative Stress; Neuro = Neuroinflammation

—

SECTION 4:

DOMAIN-SPECIFIC POSTOPERATIVE NUTRACEUTICAL STRATEGIES

4A. Targeting the Acute-to-Chronic Pain Transition (Weeks 2–12)

The transition from acute to chronic postsurgical pain (CPSP) is the central clinical concern of the postoperative period. CPSP affects approximately 10% of all surgical patients with substantial functional impairment, with higher rates in orthopedic procedures.[13] Preoperative chronic pain and opioid use — universal in this patient population — are among the strongest risk factors. Patients who had filled at least one opioid prescription in the year before surgery have a 5.3-fold risk of prolonged opioid use after surgery.[14] Poor pain alleviation (defined as pain scores ≥8 on three occasions during hospitalization) is a modifiable risk factor, with an overall rate of chronic opioid use of 25.3% at 3 months after orthopedic surgery.[15]

The 4D Protocol’s nutraceutical toolkit targets multiple nodes in this transition cascade:

Central Sensitization Prevention:

1. Magnesium (NMDA receptor antagonism) — continuous. Perioperative systemic magnesium reduces postoperative pain and opioid consumption via NMDA receptor blockade, the same mechanism exploited by ketamine.[5][6]
2. Agmatine (NMDA receptor antagonism + imidazoline receptor agonism) — restart week 1–2. Provides sustained oral NMDA antagonism complementing any intraoperative IV ketamine administered by the surgical team.
3. PEA (glial cell modulation, reducing spinal neuroinflammation) — continuous or restart week 1–2. Meta-analyses demonstrate significant pain reduction across nociceptive, neuropathic, and nociplastic pain types.[5][7][8]

Neuroinflammatory Cascade Modulation:

1. PEA (PPAR-α activation, mast cell stabilization) — continuous. PEA modulates the neuroinflammatory cascade at multiple levels: mast cell degranulation, microglial activation, and astrocyte reactivity.[7][8]
2. Curcumin (NF-κB inhibition, proinflammatory cytokine suppression) — restart week 1–2. Curcumin suppresses IL-1β, COX-2, TNF-α, and NF-κB in the dorsal root ganglia, and when co-administered with opioids produces synergistic pain reduction. Curcumin also activates endogenous opioid and endocannabinoid systems peripherally, providing analgesic mechanisms independent of its anti-inflammatory effects.[4]
3. – Melatonin (anti-neuroinflammatory, circadian rhythm restoration) — continuous. Sleep disruption is both a consequence and a driver of postoperative pain chronification; melatonin addresses both dimensions.[1]

Oxidative Stress Mitigation:

1. NAC (glutathione precursor) — restart POD 1. Surgery generates a massive oxidative stress surge; NAC provides the rate-limiting substrate for glutathione synthesis.[1][9]
2. Resveratrol (Sirt1 activation, mitochondrial antioxidant) — restart week 1–2
3. Sulforaphane (Nrf2 pathway activation) — restart week 1–2. Nrf2 activation upregulates the endogenous antioxidant defense system (SOD, catalase, glutathione peroxidase).
4. Alpha-Lipoic Acid (mitochondrial antioxidant, regenerates vitamins C and E) — restart weeks 2–4

Mitochondrial Energy Restoration:

1. CoQ10 (electron transport chain cofactor) — restart weeks 2–4. Surgical stress depletes mitochondrial energy reserves; CoQ10 repletion supports bioenergetic recovery during the rehabilitation phase.[1]
2. Acetyl-L-Carnitine (mitochondrial fatty acid transport) — restart weeks 2–4
3. Nicotinamide Riboside (NAD+ precursor) — restart weeks 2–4. NAD+ repletion supports mitochondrial bioenergetics and may reduce inflammatory states.[12]
4. D-Ribose (ATP synthesis substrate) — restart weeks 2–4

4B. Nutraceutical Synergies with Perioperative Pharmacologic Multimodal Analgesia

The ASER/POQI consensus states that multimodal analgesia is “even more relevant for the population on chronic opioids.” A network meta-analysis of 132 RCTs (23,902 participants) found that IV lidocaine (OR 0.32), ketamine (OR 0.64), and gabapentinoids (OR 0.67) reduced the incidence of CPSP at ≤6 months, with analgesics more effective at higher baseline risk — directly applicable to this high-risk population.[5][16]

The 4-D Protocol nutraceuticals complement these pharmacologic agents through parallel but non-overlapping mechanisms:

Ketamine + Magnesium + Agmatine: All three are NMDA receptor antagonists, but ketamine is typically administered IV intraoperatively (and sometimes continued as a low-dose infusion on the ward), while magnesium and agmatine provide sustained oral NMDA antagonism during the weeks-to-months recovery period when IV ketamine is no longer available. This creates a temporal bridge of NMDA receptor coverage from the operating room through the chronic pain transition window.[5][17]
Gabapentinoids + PEA + Melatonin: Gabapentin/pregabalin (if part of the patient’s chronic pain regimen) modulate presynaptic calcium channels and trigger descending noradrenergic pathways. PEA modulates glial cell activation and mast cell degranulation at the spinal level. Melatonin supports GABAergic inhibition and circadian-dependent pain modulation. These three agents target distinct nodes in the pain processing cascade.
NSAIDs/COX-2 inhibitors + Curcumin + Boswellia + Omega-3: NSAIDs inhibit COX-1/2; curcumin inhibits COX-2 and NF-κB; boswellia inhibits 5-lipoxygenase; omega-3 fatty acids generate pro-resolving mediators (resolvins, protectins). Together, these agents provide comprehensive coverage of the arachidonic acid cascade and inflammatory resolution pathways through four distinct mechanisms.
Acetaminophen + NAC: NAC is the precursor to glutathione, which is the primary pathway for acetaminophen metabolism. In patients receiving scheduled acetaminophen postoperatively (a cornerstone of multimodal analgesia), NAC supplementation supports hepatic glutathione reserves and may provide a safety margin against acetaminophen hepatotoxicity, particularly relevant in patients with compromised nutritional status.

4C. Nutraceutical Interactions with Opioids in the Postoperative Period

For this patient population on chronic opioid therapy, the interactions between nutraceuticals and opioids are clinically significant:

Curcumin-opioid synergy: Curcumin co-administered with hydromorphone produces synergistic pain reduction in preclinical models, mediated through suppression of the SDF-1/CXCR4 pathway and NF-κB-mediated proinflammatory cytokine production in the DRG. Curcumin also stimulates expression of β-endorphin and enkephalin in DRG neurons, providing an endogenous opioid mechanism of analgesia.[4][18]
Magnesium-opioid interaction: Perioperative magnesium reduces postoperative opioid consumption by approximately 7.4–10.5 mg morphine equivalents over 24 hours in orthopedic surgery. In opioid-tolerant patients, this opioid-sparing effect may help limit the degree of postoperative dose escalation above baseline.[5][6]
PEA-Opioid complementarity: PEA acts through PPAR-α and endocannabinoid system modulation — pathways entirely distinct from opioid receptors. This makes PEA a true adjunctive agent that adds analgesic coverage without competing for or modulating opioid receptor binding.[5][7]
Melatonin-opioid interaction: Melatonin has demonstrated opioid-sparing effects in perioperative settings and may attenuate opioid-induced hyperalgesia through its effects on NMDA receptor modulation and neuroinflammation.[1]

—

SECTION 5:

POSTOPERATIVE MONITORING AND DOSE ADJUSTMENT

5A. Clinic Visit 1 (4 Weeks Postoperative)

This is typically the first visit at which the patient returns to the pain management clinic. By this point, all 20 nutraceuticals should have been restarted (Phases A, B, and C complete).

Assessment priorities:

Review nutraceutical adherence — confirm all agents have been restarted and are being tolerated
Assess for any adverse effects or interactions with postoperative medications
Review biomarker results ordered at this visit (per Module 3, Section 6):
hs-CRP: Compare to preoperative baseline. Persistent elevation beyond expected surgical recovery trajectory suggests ongoing inflammation or complication.
RBC magnesium: Replete if depleted (40% of TKA patients have low magnesium by POD 1).[3]
25(OH) Vitamin D: Resume loading protocol if 30 ng/mL.
Prealbumin: Assess nutritional recovery.
Assess pain trajectory: Is pain improving as expected? Any new pain characteristics suggesting neuropathic component or central sensitization?
Assess for signs of opioid-induced hyperalgesia (OIH): Paradoxical increase in pain despite adequate opioid dosing, diffuse pain beyond the surgical site, allodynia. OIH is mediated by NMDA receptor activation — the same pathway targeted by magnesium and agmatine.[17]

Domain-specific dose adjustments:

If hs-CRP remains elevated: Consider increasing curcumin dose, adding or increasing boswellia, ensuring omega-3 dose is at 4 g/day EPA/DHA
If pain has neuropathic features: Prioritize PEA (consider dose increase to 1,200 mg/day if tolerated), ensure agmatine is at therapeutic dose, confirm magnesium adequacy
If fatigue/poor rehabilitation progress: Prioritize mitochondrial domain agents (CoQ10, ALC, NR, D-Ribose), ensure B-vitamin adequacy
If sleep disruption persists: Consider melatonin dose increase (up to 10 mg), ensure magnesium is at adequate dose

5B. Clinic Visit 2 (8 Weeks Postoperative)

This visit falls within the critical CPSP transition window (defined as pain persisting ≥2 months after surgery).[13]

Assessment priorities:

1. Formal CPSP risk assessment: Pain not improving as expected, new pain characteristics (burning, allodynia, hyperalgesia), sleep disruption, mood changes, functional limitation beyond expected recovery trajectory
2. Repeat hs-CRP: Should be trending toward preoperative baseline. Persistent elevation at 8 weeks is a red flag.
3. The NIH Acute to Chronic Pain Signatures (A2CPS) program has identified candidate biomarkers including genomic, proteomic, metabolomic, lipidomic, neuroimaging, psychophysical, psychological, and behavioral measures for the transition to CPSP. While most of these are not yet clinically available, the 4D Protocol’s existing biomarker panel (hs-CRP, homocysteine, Omega-3 Index, vitamin levels) provides a practical surrogate for monitoring the inflammatory and metabolic dimensions of this transition.[19]
4. Cytokine profiling (if available): Higher baseline concentrations of GM-CSF, IL-1β, IL-2, and IL-12 p70 are associated with more severe acute postsurgical pain, while lower postoperative concentrations of IL-6, IL-8, and IL-13 are associated with higher CPSP risk — suggesting that an adequate acute inflammatory response may actually be protective against chronification.[20]
5. Neutrophil-lymphocyte ratio (NLR): A postoperative-to-preoperative NLR change ratio ≥5 significantly correlates with CPSP and affected quality of life, and may serve as an accessible, low-cost biomarker for early identification of at-risk patients.[21]

Domain-specific adjustments at 8 weeks:

If CPSP transition is suspected: Intensify neuroinflammation domain coverage (PEA, agmatine, curcumin), ensure NMDA antagonism is maximized (magnesium, agmatine), consider adding or increasing sulforaphane for Nrf2 activation
If recovery is on track: Maintain current regimen, begin planning transition to long-term 4D Protocol maintenance

5C. Clinic Visit 3 (12 Weeks Postoperative)

Assessment priorities:

1. Full 4-D Protocol biomarker panel reassessment (compare to preoperative baseline)
2. Formal determination: Has CPSP developed? If pain persists at 12 weeks with functional impairment, this meets the ICD-11 definition of chronic postsurgical pain.
3. Transition planning: If recovery is on track, transition from perioperative protocol to standard 4D Protocol chronic pain management. If CPSP has developed, the 4D Protocol’s domain-guided approach becomes the primary framework for ongoing management.
4. Opioid trajectory assessment: Is the patient trending back toward preoperative baseline opioid dose? If opioid dose remains elevated above baseline at 12 weeks, this warrants specific attention and may indicate inadequately treated pain, OIH, or CPSP development.

—

SECTION 6:

SPECIAL CONSIDERATIONS

6A. Spine Fusion Patients

More conservative Phase B restart timeline (days 10–14 rather than 7–10) for all bleeding-risk agents
Bone healing considerations: Vitamin D3, magnesium, and calcium adequacy are critical for fusion success. Ensure these are maintained at optimal levels throughout the 12-week period.
NSAIDs are often avoided after spine fusion due to concerns about impaired bone healing (though evidence is mixed). This makes the nutraceutical anti-inflammatory agents (curcumin, boswellia, omega-3) even more important as non-NSAID anti-inflammatory coverage.
Curcumin’s anti-inflammatory mechanism (NF-κB inhibition) is distinct from COX inhibition and has not been associated with impaired bone healing in preclinical studies, though specific clinical data in spine fusion are lacking.

6B. Total Joint Arthroplasty Patients

Standard Phase B restart timeline (days 7–10) is appropriate
Diosmin/hesperidin supplementation for postoperative swelling (detailed in Module 3, Section 4) complements the nutraceutical restart protocol
Essential amino acid supplementation (detailed in Module 3, Section 2) should be coordinated with the nutraceutical restart — EAA and nutraceuticals serve complementary but distinct roles
Quadriceps preservation is a primary functional goal: EAA supplementation, adequate protein intake, and mitochondrial domain agents (CoQ10, ALC, NR) all support muscle recovery

6C. Patients with Inadequate Preoperative Optimization

Some patients may present for surgery without the benefit of the full 4-week preoperative optimization window (Module 2, Phase 1). In these cases:

Prioritize the Tier 1 universal agents (omega-3, vitamin D3, magnesium, B-complex, melatonin) for immediate postoperative initiation even if they were not started preoperatively
The postoperative period becomes the primary therapeutic window rather than a continuation of preoperative optimization
Biomarker assessment should still be performed at the first postoperative clinic visit to guide domain-specific nutraceutical selection

6D. Managing Nutraceutical Pill Burden

The full 4D Protocol regimen of nutraceuticals represents a significant pill burden, which may be poorly tolerated in the early postoperative period when patients are already managing multiple prescription medications, experiencing nausea, and having difficulty with oral intake.

Prioritization strategy for the early postoperative period:

1. Essential (start POD 0–2): Omega-3, magnesium, melatonin, vitamin D3, B-complex (5 agents)
2. High priority (start when tolerating full oral intake): NAC, PEA, curcumin (3 agents — add as tolerated)
3. Standard priority (add at clinic visits): Remaining agents per domain profile
4. The full regimen should be restored by the 4-week clinic visit in most patients

—

SECTION 7:

INTEGRATION WITH PHARMACOLOGIC MULTIMODAL ANALGESIA — RECOMMENDATIONS FOR SURGEON COMMUNICATION

The following nutraceutical-pharmacologic integration points should be communicated to the surgical team as part of the surgeon communication document:

1. Omega-3, magnesium, melatonin, vitamin D3, and B-complex are being continued through surgery and should be resumed postoperatively as soon as oral intake is tolerated. These are nutritional/vitamin supplements with demonstrated perioperative benefit and no identified surgical risks.

2. IV magnesium sulfate administered intraoperatively or in the PACU is complementary to the patient’s oral magnesium supplementation. A meta-analysis of 25 RCTs (1,461 patients) demonstrated that perioperative systemic magnesium reduces postoperative pain scores and opioid consumption. A 2026 RCT in lower extremity orthopedic surgery confirmed that adjunctive IV magnesium sulfate (50 mg/kg bolus + 15 mg/kg/hr infusion) reduced postoperative pain scores and opioid requirements.[5][6]

3. Perioperative ketamine infusion is strongly recommended for this opioid-tolerant population. The ASER/POQI consensus identifies ketamine as one of the few adjuncts specifically studied in patients on preoperative opioids, with an RCT demonstrating reduced opioid consumption up to 24 hours after lumbar fusion in opioid-dependent patients. Ketamine’s NMDA receptor antagonism directly addresses opioid tolerance and opioid-induced hyperalgesia. The patient’s oral magnesium and (when restarted) agmatine provide sustained NMDA antagonism that bridges the gap after IV ketamine is discontinued.[5][17]

4. Curcumin, boswellia, quercetin, and resveratrol were held 2 weeks preoperatively for bleeding risk and will be restarted by the pain management team once hemostasis is assured (typically days 7–14). These agents provide anti-inflammatory coverage through mechanisms distinct from NSAIDs and do not carry the bone healing concerns associated with COX inhibition.

—

SECTION 8:

DOCUMENTATION AND TRANSITION (COMPLETE)

At each postoperative clinic visit, document:

1. Current nutraceutical regimen with doses and dates restarted

2. Biomarker results with comparison to preoperative baseline

3. 4-D domain profile reassessment scores

4. Pain trajectory assessment (improving, stable, worsening, new characteristics)

5. Opioid dose trajectory (trending toward baseline, stable above baseline, escalating)

6. Functional recovery assessment

7. Any nutraceutical dose adjustments made and rationale

At the 12-week visit, generate a transition summary that:

Compares preoperative and 12-week biomarker panels side by side, identifying which biomarkers improved, worsened, or remained stable through the perioperative period
Documents the pain trajectory over the full perioperative period, including pain scores at each visit, pain character changes, and any new pain features
Identifies any new domain imbalances that emerged during the surgical stress response (e.g., a patient who entered surgery with a predominantly inflammatory phenotype may emerge with new mitochondrial dysfunction features due to surgical metabolic stress)
Establishes the long-term 4D Protocol maintenance regimen, which may differ from the preoperative regimen based on postoperative biomarker findings and clinical response
Documents the opioid trajectory: preoperative baseline dose → peak postoperative dose → current dose at 12 weeks → plan for continued taper if applicable
Summarizes dietary and nutritional status: protein intake adequacy, anti-inflammatory dietary pattern adherence, weight trajectory, and any persistent nutritional deficiencies requiring ongoing supplementation

—

SECTION 9:

TRANSITION DECISION FRAMEWORK AT 12 WEEKS

At the 12-week postoperative visit, one of three clinical trajectories will be evident. Each trajectory dictates a different nutraceutical management path going forward:

Trajectory A: Successful Recovery (Expected in 60–70% of Patients)

Clinical features: Pain improving as expected, functional recovery on track, opioid dose trending toward or at preoperative baseline, biomarkers normalizing.

Nutraceutical plan:

Transition to standard 4D Protocol chronic pain management regimen
Nutraceutical selection guided by 12-week biomarker panel and updated domain profile
Perioperative-specific additions (e.g., vitamin C for CRPS prevention, diosmin/hesperidin for swelling) can be discontinued
Continue all domain-specific agents indicated by the patient’s chronic pain profile

Trajectory B: Delayed Recovery / Emerging CPSP (Expected in ~20–30% of Patients)

Clinical features: Pain not improving as expected but not clearly chronic, functional recovery slower than anticipated, opioid dose above preoperative baseline, some biomarkers persistently abnormal.

Nutraceutical plan:

Intensify domain-specific coverage based on biomarker findings
If hs-CRP persistently elevated: Maximize anti-inflammatory domain (curcumin at highest tolerated dose, omega-3 at 4 g/day, boswellia, quercetin)
If neuropathic pain features present: Maximize neuroinflammation domain (PEA at 1,200 mg/day, agmatine, melatonin at 10 mg)
If fatigue and poor rehabilitation: Maximize mitochondrial domain (CoQ10, ALC, NR, D-Ribose)
Continue vitamin C supplementation beyond the standard 50-day course
Reassess at 16 weeks with repeat biomarker panel
Consider formal CPSP evaluation and additional pharmacologic interventions (e.g., gabapentinoid adjustment, duloxetine initiation if not already prescribed)

Trajectory C: Established CPSP (Expected in 10% of Patients)

Clinical features: Pain persisting at or above preoperative levels with new characteristics (burning, allodynia, hyperalgesia), significant functional impairment, opioid dose escalated above baseline with inadequate relief, biomarkers suggesting ongoing inflammation or neuroinflammation.[1]

Nutraceutical plan:

Full 4-D Protocol domain profiling becomes the primary management framework
The perioperative protocol transitions seamlessly into the chronic pain management protocol, with the advantage that the patient’s preoperative biomarker baseline provides a reference point for identifying surgery-induced domain shifts
Aggressive multi-domain nutraceutical coverage with emphasis on neuroinflammation (PEA, agmatine, curcumin) and central sensitization prevention (magnesium, agmatine)
Dietary anti-inflammatory pattern becomes a long-term commitment rather than a perioperative intervention
Coordinate with the surgical team regarding any surgical complications or revision considerations
Consider referral for psychological support (CBT for chronic pain, acceptance and commitment therapy) if not already in place — psychological factors are among the strongest predictors of CPSP development[1][2]

—

SECTION 10:

COMPLETE PERI-OPERATIVE TIMELINE SUMMARY (MODULES 1–4 INTEGRATED)

The following provides a consolidated view of the entire perioperative protocol across all four modules:

6 Weeks Preoperative (Visit 1):

Module 1: Nutritional screening (MNA-SF, MUST), dietary assessment, anti-inflammatory diet initiation, laboratory panel ordered
Module 2: 4D domain profiling, nutraceutical regimen review, Phase 1 optimization begins (all indicated nutraceuticals at full dose)

4 Weeks Preoperative (Visit 2):

Module 1: Lab results reviewed, nutritional deficiencies addressed, dietary adherence reinforced, protein optimization confirmed
Module 2: Nutraceutical dose adjustments based on biomarkers, patient education on upcoming hold schedule with written instructions and specific dates

2 Weeks Preoperative (Hold Date):

Module 2: Category C nutraceuticals discontinued (13 agents), Category A agents continue (7 agents), NAC continues until 24 hours preop
Module 1: Dietary intensification to compensate for nutraceutical hold gap
Surgeon communication document delivered with supplement management summary

Day of Surgery:

Module 2: Category A nutraceuticals taken with sip of water per anesthesia protocol
Module 1: NPO per anesthesia guidelines

POD 0–2:

Module 3: Oral nutrition resumed ASAP per ERAS, protein-dense liquids, hydration
Module 4: Category A nutraceuticals resumed, NAC restarted POD 1

Days 7–14:

Module 3: Protein targets 1.5–2.0 g/kg/day, vitamin C 500–1,000 mg/day, EAA supplementation
Module 4: Phase B restart — curcumin, resveratrol, quercetin, boswellia, sulforaphane, taurine, agmatine, PEA (if held)

Weeks 2–4:

Module 3: Protein targets maintained, anti-inflammatory diet intensification, micronutrient monitoring
Module 4: Phase C restart — CoQ10, ALA, ALC, NR, D-Ribose

4 Weeks Post-operative (Visit 1):

Module 3: Biomarker panel (hs-CRP, Mg, vitamin D, prealbumin, CBC), dietary assessment, protein adequacy review
Module 4: Full nutraceutical regimen confirmed, adherence review, domain-specific dose adjustments

8 Weeks Postoperative (Visit 2):

Module 3: Repeat hs-CRP, Omega-3 Index, CPSP risk assessment, dietary adherence
Module 4: CPSP transition assessment, domain-specific intensification if needed, NLR calculation

12 Weeks Postoperative (Visit 3):

Module 3: Full biomarker panel reassessment, nutritional screening readministration, long-term dietary plan
Module 4: Full 4D domain profile reassessment, transition decision (Trajectory A/B/C), long-term nutraceutical regimen established, opioid trajectory documented
Transition summary generated comparing preoperative and 12-week status across all domains

References

Transition From Acute to Chronic Pain After Surgery. Glare P, Aubrey KR, Myles PS. Lancet (London, England). 2019;393(10180):1537-1546. doi:10.1016/S0140-6736(19)30352-6.
Identifying Risk Factors for Chronic Postsurgical Pain and Preventive Measures: A Comprehensive Update. Pergolizzi JV, LeQuang JA, Magnusson P, Varrassi G. Expert Review of Neurotherapeutics. 2023 Jul-Dec;23(12):1297-1310. doi:10.1080/14737175.2023.2284872.
The Impact of Preoperative Central Sensitization and Novel Mitigation Strategies on Outcomes Following Spinal Surgery: A Comprehensive Narrative Review. Karami M, Kahn HA, Fakhrzadegan M, et al. The Spine Journal : Official Journal of the North American Spine Society. 2026;:S1529-9430(26)00106-3. doi:10.1016/j.spinee.2026.04.006.
Perioperative Opioid Analgesia-When Is Enough Too Much? A Review of Opioid-Induced Tolerance and Hyperalgesia. Colvin LA, Bull F, Hales TG. Lancet (London, England). 2019;393(10180):1558-1568. doi:10.1016/S0140-6736(19)30430-1.
American Society for Enhanced Recovery and Perioperative Quality Initiative Joint Consensus Statement on Perioperative Management of Patients on Preoperative Opioid Therapy. Edwards DA, Hedrick TL, Jayaram J, et al. Anesthesia and Analgesia. 2019;129(2):553-566. doi:10.1213/ANE.0000000000004018.
Treatment of Opioid Use Disorder in the General Hospital. Margo C. Funk MD MA, Sara Nash MD, Allison Smith MD, et al. American Psychiatric Association (2022).
Central Sensitization: When It Is Not “All in Your Head”. Mohabbat AB, Wilkinson JM. American Family Physician. 2023;107(1):92-96.
Central Sensitisation in Chronic Pain Conditions: Latest Discoveries and Their Potential for Precision Medicine. Nijs J, George SZ, Clauw DJ, et al. The Lancet. Rheumatology. 2021;3(5):e383-e392. doi:10.1016/S2665-9913(21)00032-1.
Mechanisms of Chronic Postsurgical Pain. Tassou A, Richebe P, Rivat C. Regional Anesthesia and Pain Medicine. 2025;50(2):77-85. doi:10.1136/rapm-2024-105964.
Low-Dose Ketamine in Painful Orthopaedic Surgery: A Systematic Review and Meta-Analysis. Riddell JM, Trummel JM, Onakpoya IJ. British Journal of Anaesthesia. 2019;123(3):325-334. doi:10.1016/j.bja.2019.05.043.
Treatment of Acute Postoperative Pain. Wu CL, Raja SN. Lancet (London, England). 2011;377(9784):2215-25. doi:10.1016/S0140-6736(11)60245-6.
Opioid-Induced Hyperalgesia in Clinical Anesthesia Practice: What Has Remained From Theoretical Concepts and Experimental Studies?. Weber L, Yeomans DC, Tzabazis A. Current Opinion in Anaesthesiology. 2017;30(4):458-465. doi:10.1097/ACO.0000000000000485.
Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. Chou R, Gordon DB, de Leon-Casasola OA, et al. The Journal of Pain. 2016;17(2):131-57. doi:10.1016/j.jpain.2015.12.008.
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Cohen SP, Bhatia A, Buvanendran A, et al. Regional Anesthesia and Pain Medicine. 2018;43(5):521-546. doi:10.1097/AAP.0000000000000808.
AAOS/METRC Clinical Practice Guideline Summary: Pharmacologic, Physical, and Cognitive Pain Alleviation for Musculoskeletal Extremity/Pelvis Surgery. Patzkowski JC, Patzkowski MS. The Journal of the American Academy of Orthopaedic Surgeons. 2022;30(18):e1152-e1160. doi:10.5435/JAAOS-D-22-00047.
Perioperative Ketamine for Postoperative Pain Management in Patients With Preoperative Opioid Intake: A Systematic Review and Meta-Analysis. Meyer-Frießem CH, Lipke E, Weibel S, et al. Journal of Clinical Anesthesia. 2022;78:110652. doi:10.1016/j.jclinane.2022.110652.
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Schwenk ES, Viscusi ER, Buvanendran A, et al. Regional Anesthesia and Pain Medicine. 2018;43(5):456-466. doi:10.1097/AAP.0000000000000806.
Adjunctive Intravenous Magnesium Sulfate for Postoperative Pain and Opioid Reduction in Lower Extremity Orthopedic Surgery: A Double-Blind Randomized Controlled Trial. Muhammad AR, Sukmono RB, Tantri AR, Wiyarta E. Journal of Clinical Medicine. 2026;15(5):2055. doi:10.3390/jcm15052055.
Perioperative Systemic Magnesium to Minimize Postoperative Pain: A Meta-Analysis of Randomized Controlled Trials. De Oliveira GS, Castro-Alves LJ, Khan JH, McCarthy RJ. Anesthesiology. 2013;119(1):178-90. doi:10.1097/ALN.0b013e318297630d.
The Efficacy and Safety of Regional Nerve Blocks in Total Hip Arthroplasty: Systematic Review and Direct Meta-Analysis. Fillingham YA, Hannon CP, Kopp SL, et al. The Journal of Arthroplasty. 2022;37(10):1922-1927.e2. doi:10.1016/j.arth.2022.04.035.
Regional Anaesthesia Modalities for Primary Total Hip Arthroplasty: A Systematic Review and Component Network Meta-Analysis. Lee KH, Wang JC, Chang CY, et al. British Journal of Anaesthesia. 2025;:S0007-0912(25)00256-9. doi:10.1016/j.bja.2025.04.019.

Emphasis on Education

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

Should you wish more information regarding any of the subjects listed – or not listed – here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

For more information, please contact Accurate Clinic.

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.